Castle Biosciences
Castle Biosciences Inc is an American commercial-stage dermatologic diagnostics company focused on personalized clinical test solutions. The company develops and commercializes gene expression profiling diagnostic tests, including DecisionDx-Melanoma and DecisionDx-SCC, to guide treatment decisions in skin cancers and Barrett's esophagus. Main revenue drivers comprise diagnostic test billing fees paid by Medicare, commercial health insurers, and clinical healthcare providers. Castle Biosciences serves dermatologists, mohs surgeons, dermatopathologists, and gastroenterologists across the United States. The company holds a prominent position in precision gene expression profiling tests for dermatologic oncology. Headquartered in Friendswood, Texas, Castle Biosciences Inc is listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Castle Biosciences.
- Legal name
- CASTLE BIOSCIENCES
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Cancer Profiling, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding Castle Biosciences
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.06 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)